Dexcom (Nadsaq:DXCM) today reported second-quarter financial results that came in ahead of the consensus forecast.
The company also announced a planned CEO transition — read more about that HERE.
Shares of DXCM sat unchanged at $89.06 apiece in post-market trading today. (They fell by more than 9% the next day, July 31, to $80.88 apiece.)
The San Diego-based continuous glucose monitor maker reported profits of $179.8 million. That equals 45¢ per share on sales of $1.16 billion for the three months ended June 30, 2025.
Dexcom recorded a 25.3% bottom-line gain on a sales increase of 15.2% year-over-year.
Read our free Diabetes Tech Special Report covering companies like Dexcom HERE>>
Adjusted to exclude one-time items, earnings per share came in at 48¢. That landed 3¢ ahead of expectations on Wall Street. Sales also topped estimates as experts forecast $1.12 billion in revenue.
“During the quarter, Dexcom delivered strong revenue results, presented compelling clinical data at ADA, and further advocated for expanded coverage in key growth markets,” said Kevin Sayer, Dexcom chair and CEO. “In the second half of 2025, we look forward to continuing our commercial momentum while advancing our product portfolio with the highly-anticipated launch of our Dexcom G7 15-day system.”
Dexcom raised its full-year outlook to revenues between $4.6 billion and $4.625 billion, marking 14-15% growth. It previously projected $4.6 billion in sales. The company reaffirmed a non-GAAP gross profit margin guidance of approximately 62%.
Dexcom’s CTO Girish Naganathan will speak about the future of connected health at DeviceTalks West, Oct. 15–16, 2025 in Santa Clara, California. Register at West.DeviceTalks.com.
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang call Dexcom a “2025 Top Pick” with a “Buy rating.”
“This Q2 print was just as we hoped, including a strong U.S. beat, demonstrated commercial team stability, broader payor coverage, sufficient customer supply paired with continued efforts to rebuild internal inventory, and controlled spending,” the analysts wrote. “We think the 2025 outlook leaves room for a beat-and-raise second half, and we’d be buyers of the stock here.”
